A Personalized, At-Home Breakthrough
One of the most significant treatments for Parkinson’s disease in decades
Addressing Major Unmet Needs in Parkinson's
Pivotal Trial to Confirm Sustained Efficacy
ADDRESSING MAJOR UNMET NEEDS
A Breakthrough Therapy for People Living with Parkinson’s Disease
Specialized phototherapy addresses both motor and non-motor symptoms
Over 11 million people worldwide live with Parkinson’s disease (PD), a number that is projected to double over the next 20 years. As with so many other neurodegenerative diseases, there have been no major breakthroughs in Parkinson’s disease in decades.
Our personalized at-home device promises to be one of the most significant therapeutic breakthroughs in Parkinson’s disease in decades. We have seen large improvements in our proof-of-concept studies – especially in addressing major unmet needs in Parkinson’s. We are initiating a pivotal trial of our key product, Celeste® specialized phototherapy, to confirm safety and sustained efficacy.
Despite the efficacy of dopaminergic drugs, people with PD continue to experience difficulties with unresolved motor symptoms and non-motor symptoms (e.g., sleep disorders, fatigue, and mood and cognitive problems). Impaired function significantly reduces quality of life for many, often preventing those living with PD from working, exercising, socializing, and doing the things they want to do.
We invite you to join us to improve the lives of individuals suffering from neurodegenerative diseases.
Seeing Specialized Phototherapy Clearly
Our non-invasive specialized phototherapy is well on its way to becoming a physician-prescribed standard of care.
When it comes to motor and non-motor symptoms of Parkinson’s, here’s what we’re seeing so far.
and enjoyed improved quality of life.
LIFESTYLE FRIENDLY PROTOCOL
Improving Life for People
with Neurodegenerative Diseases
While our first focus is Parkinson’s, we aim to extend our therapeutic platform
to Alzheimer’s and other neurodegenerative diseases,
promising relief and even healing for millions.
Join us in improving lives by supporting our innovation
and participating in our clinical research
Celeste® Light for PD Trial to be Presented at World Parkinson’s Congress PhotoPharmics to showcase groundbreaking research at the prestigious international event July 5-7, 2023 PhotoPharmics, a leading innovator in Parkinson's disease, today announced that it will be...
PhotoPharmics to Present at MTI All Stars Investor Showcase DeviceTalks in Boston on May 10-11 to feature pitches from PhotoPharmics and other leading startups PhotoPharmics today announced CEO Kent Savage has been invited to present at the inaugural MTI All Stars...
When most people think of Parkinson’s Disease (PD), the first symptom to come to mind are physical tremors and other movement symptoms. However, most people with Parkinson’s experience a wide range of non-motor symptoms that can often be more disruptive to their daily...
“What would I do without my caregiver?” Many people with Parkinson’s disease ask themselves some form of this question every single day. Caregivers come in all shapes and forms, but they all have one thing in common: The work they do is absolutely critical. But it’s...
Innovative medical devices and diagnostics can get to patients and providers sooner under the U.S. Food and Drug Administration’s (FDA) Breakthrough Device Program. The program provides a special regulatory Breakthrough Device Designation for medical products that...